Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The company analyzed GLP-1 benefits and access for its patient population and found that currently 69% do not have coverage for this class of drugs to treat diabetes or for weight loss, a significant decline in coverage in the past seven months
Yamashita M, Nonaka T, et al
On October 17, 2024, FDA joined California regulatory authorities at the Fullerton Wellness facility and observed conditions that could cause the drugs produced by the company to become contaminated
Furthermore, several notable features distinguish it within the peptide research category: Pre-filled injection pen system for controlled handling High-concentration 20mg formulation for laboratory reference Stabilized peptide matrix for improved structural integrity Designed for research and analytical applications only Engineered for consistency across batch formulations Additionally, these features have been integrated to support reproducible research outcomes
